Santen Oy
🇫🇮Finland
A Study to Evaluate Pharmacokinetics of Tafluprost Ophthalmic Solution (0.0015%) in Pediatric Patients With Glaucoma or Ocular Hypertension
Phase 1
Completed
- Conditions
- GlaucomaOcular Hypertension
- Interventions
- Drug: Preservative free tafluprost opthalmic solution
- First Posted Date
- 2014-04-03
- Last Posted Date
- 2017-10-10
- Lead Sponsor
- Santen Oy
- Target Recruit Count
- 17
- Registration Number
- NCT02102750
- Locations
- 🇬🇧
Moorfields Eye Hospital, London, United Kingdom
🇺🇸Childrens Hospital of Philadelphia (CHOP), Philadelphia, Pennsylvania, United States
Pharmacokinetics, Safety and Tolerability of the Preservative-free Fixed Dose Combination of Tafluprost 0.0015% and Timolol 0.5% Eye Drops
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: Preservative free tafluprost 0.0015% eye dropsDrug: Preservative free timolol 0.5% eye dropsDrug: Preservative free FDC of tafluprost 0.0015% and timolol 0.5% eye drops
- First Posted Date
- 2011-09-15
- Last Posted Date
- 2012-06-08
- Lead Sponsor
- Santen Oy
- Target Recruit Count
- 15
- Registration Number
- NCT01434888
- Locations
- 🇫🇮
Kuopio University Hospital Eye Clinic, Kuopio, Finland
Tafluprost-Timolol Fixed Dose Combination Non-Inferiority Study Against Concomitant Administrations
Phase 3
Completed
- Conditions
- Ocular HypertensionOpen-angle Glaucoma
- Interventions
- Drug: Timolol and TafluprostDrug: Fixed Dose Combination of tafluprost and timolol
- First Posted Date
- 2011-03-01
- Last Posted Date
- 2012-06-08
- Lead Sponsor
- Santen Oy
- Target Recruit Count
- 401
- Registration Number
- NCT01306461
Tafluprost-Timolol Preservative-free Fixed Dose Combination (FDC) Superiority Study Against Monotherapies
Phase 3
Completed
- Conditions
- Ocular HypertensionOpen-angle Glaucoma
- Interventions
- Drug: Timolol/ FDC/ Placebo/ Tafluprost
- First Posted Date
- 2011-02-09
- Last Posted Date
- 2013-03-13
- Lead Sponsor
- Santen Oy
- Target Recruit Count
- 600
- Registration Number
- NCT01292460
- Locations
- 🇫🇮
Eye Clinic, University Hospital of Oulu, Oulu, Finland
🇫🇮Eye clinic, University Hospital of Kuopio, Kuopio, Finland
Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost to Preservative Free Tafluprost Eye Drops
- First Posted Date
- 2010-03-16
- Last Posted Date
- 2013-05-31
- Lead Sponsor
- Santen Oy
- Target Recruit Count
- 185
- Registration Number
- NCT01087671
Pharmacodynamics of Tafluprost 0.0015% Eye Drops: a Comparison Between the Preserved and Unpreserved Formulation
Phase 3
Completed
- Conditions
- Open-Angle GlaucomaOcular Hypertension
- Interventions
- First Posted Date
- 2009-06-11
- Last Posted Date
- 2010-12-28
- Lead Sponsor
- Santen Oy
- Target Recruit Count
- 43
- Registration Number
- NCT00918346
- Locations
- 🇩🇪
Ulrich Richter's surgery, Regensburg, Germany
🇫🇮Oulu University Hospital, Oulu, Finland
🇩🇪Praxis Dr. Hamacher, Starnberg, Germany
Interaction Study of Timolol Eye Drops and Paroxetine Capsules
- First Posted Date
- 2009-04-09
- Last Posted Date
- 2010-01-28
- Lead Sponsor
- Santen Oy
- Target Recruit Count
- 12
- Registration Number
- NCT00879099
- Locations
- 🇫🇮
University of Helsinki, Department of Clinical Pharmacology, Helsinki, Biomedicum, Finland
Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost 0.005% to Preservative Free Tafluprost Eye Drops
- First Posted Date
- 2008-01-17
- Last Posted Date
- 2009-01-12
- Lead Sponsor
- Santen Oy
- Target Recruit Count
- 150
- Registration Number
- NCT00596791
- Locations
- 🇫🇮
Finn-Medi Research Oy, Tampere, Finland
© Copyright 2025. All Rights Reserved by MedPath